Sign up to save your podcasts
Or
Share Pliant Therapeutics Raises $100M in Series C
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Pliant Therapeutics Raises $100M in Series C
Tweet SOUTH SAN FRANCISCO, CA, Pliant Therapeutics today announced that it has raised $100 million in a Series C financing.
To export Pliant Therapeutics funding data to PDF and Excel, clickClick here for more funding data on Pliant TherapeuticsTo export Pliant Therapeutics funding data to PDF and Excel, click here Pliant Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced that it has raised $100 million in a Series C financing.
Existing investors participating in the financing included Eventide Asset Management, Cowen Healthcare Investments, Schroder Adveq, Menlo Ventures, SCubed Capital, Agent Capital and undisclosed institutional investors.
About Pliant TherapeuticsPliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel targeted therapies to slow or halt the progression of multiple life-threatening fibrotic diseases.
The company's lead product candidate, PLN-74809, is currently in Phase 2 testing for IPF. | To read full story, visit https://startuparound.com/read/1583283606.6011145/Pliant-Therapeutics-Raises-$100M-in-Series-C?ref=audio_experience
View all episodes
By Startup AroundTweet SOUTH SAN FRANCISCO, CA, Pliant Therapeutics today announced that it has raised $100 million in a Series C financing.
To export Pliant Therapeutics funding data to PDF and Excel, clickClick here for more funding data on Pliant TherapeuticsTo export Pliant Therapeutics funding data to PDF and Excel, click here Pliant Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced that it has raised $100 million in a Series C financing.
Existing investors participating in the financing included Eventide Asset Management, Cowen Healthcare Investments, Schroder Adveq, Menlo Ventures, SCubed Capital, Agent Capital and undisclosed institutional investors.
About Pliant TherapeuticsPliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel targeted therapies to slow or halt the progression of multiple life-threatening fibrotic diseases.
The company's lead product candidate, PLN-74809, is currently in Phase 2 testing for IPF. | To read full story, visit https://startuparound.com/read/1583283606.6011145/Pliant-Therapeutics-Raises-$100M-in-Series-C?ref=audio_experience